Mukherji B, Chakraborty N G, Yamasaki S, Okino T, Yamase H, Sporn J R, Kurtzman S K, Ergin M T, Ozols J, Meehan J
Department of Medicine, University of Connecticut School of Medicine, Farmington 06030, USA.
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82. doi: 10.1073/pnas.92.17.8078.
Human melanoma cells can process the MAGE-1 gene product and present the processed nonapeptide EADPTGHSY on their major histocompatibility complex class I molecules, HLA-A1, as a determinant for cytolytic T lymphocytes (CTLs). Considering that autologous antigen presenting cells (APCs) pulsed with the synthetic nonapeptide might, therefore, be immunogenic, melanoma patients whose tumor cells express the MAGE-1 gene and who are HLA-A1+ were immunized with a vaccine made of cultured autologous APCs pulsed with the synthetic nonapeptide. Analyses of the nature of the in vivo host immune response to the vaccine revealed that the peptide-pulsed APCs are capable of inducing autologous melanoma-reactive and the nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic disease sites.
人黑色素瘤细胞能够处理MAGE-1基因产物，并在其主要组织相容性复合体I类分子HLA-A1上呈递处理后的九肽EADPTGHSY，作为细胞毒性T淋巴细胞（CTL）的决定簇。因此，考虑到用合成九肽脉冲处理的自体抗原呈递细胞（APC）可能具有免疫原性，对肿瘤细胞表达MAGE-1基因且为HLA-A1阳性的黑色素瘤患者，用经合成九肽脉冲处理的培养自体APC制成的疫苗进行免疫。对疫苗的体内宿主免疫反应性质的分析表明，肽脉冲APC能够在免疫部位和远处转移病灶部位原位诱导自体黑色素瘤反应性和九肽特异性CTL。
